NO20051779L - Immunisering mot autologt ghrelin - Google Patents

Immunisering mot autologt ghrelin

Info

Publication number: NO20051779L
Authority: NO; Norway
Prior art keywords: ghrelin; methods; autologous; autologous ghrelin; immunization
Prior art date: 2002-09-12

Application number

NO20051779A

Other languages

English (en)

Norwegian (no)

Other versions

NO20051779D0 (no

Inventor

Steen Klysner

Rine Elisabeth Gottscha Boving

Original Assignee

Pharmexa As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-12

Filing date

2005-04-11

Publication date

2005-04-11

2005-04-11 Application filed by Pharmexa As filed Critical Pharmexa As

2005-04-11 Publication of NO20051779D0 publication Critical patent/NO20051779D0/no

2005-04-11 Publication of NO20051779L publication Critical patent/NO20051779L/no

Links

101800001586 Ghrelin Proteins 0.000 title abstract 6
GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 4
230000003053 immunization Effects 0.000 title abstract 3
238000002649 immunization Methods 0.000 title abstract 3
102000012004 Ghrelin Human genes 0.000 title 1
102400000442 Ghrelin-28 Human genes 0.000 abstract 5
238000000034 method Methods 0.000 abstract 4
239000008194 pharmaceutical composition Substances 0.000 abstract 2
238000002255 vaccination Methods 0.000 abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
-1 Ghrelin nucleic acid Chemical class 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000016784 immunoglobulin production Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
150000007523 nucleic acids Chemical group 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

NO20051779A 2002-09-12 2005-04-11 Immunisering mot autologt ghrelin NO20051779L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41016402P	2002-09-12	2002-09-12
DKPA200201345		2002-09-12
PCT/DK2003/000592 WO2004024183A1 (en)	2002-09-12	2003-09-12	Immunization against autologous ghrelin

Publications (2)

Publication Number	Publication Date
NO20051779D0 NO20051779D0 (no)	2005-04-11
NO20051779L true NO20051779L (no)	2005-04-11

Family

ID=31995413

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051779A NO20051779L (no)	2002-09-12	2005-04-11	Immunisering mot autologt ghrelin

Country Status (7)

Country	Link
EP (1)	EP1539232A1 (de)
JP (1)	JP2006504413A (de)
AU (1)	AU2003263150A1 (de)
CA (1)	CA2498739A1 (de)
MX (1)	MXPA05002699A (de)
NO (1)	NO20051779L (de)
WO (1)	WO2004024183A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005097830A2 (en) *	2004-04-07	2005-10-20	Aditech Pharma Ab	Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
WO2005097831A2 (en) *	2004-04-07	2005-10-20	Gastrotech Pharma A/S	Uses of isolated binding members capable of binding specifically to secretagogues
GB0411014D0 (en) *	2004-05-18	2004-06-23	Haptogen Ltd	Methods for the control treatment and management of obesity
US7479271B2 (en) *	2005-02-23	2009-01-20	Eli Lilly And Company	Humanized anti-ghrelin antibodies
US8992928B2 (en)	2006-02-11	2015-03-31	Victor Raso	Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
EP2493910A1 (de)	2009-10-30	2012-09-05	Tranzyme Pharma, Inc.	Makrozyklische ghrelin-rezeptorantagonisten und gegenagonisten sowie verwendungsverfahren dafür

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2402563A1 (en) *	1999-12-23	2001-07-26	Hyseq, Inc.	Novel nucleic acids and polypeptides
US20010020012A1 (en) *	2000-02-01	2001-09-06	Andersen Maibritt Bansholm	Use of compounds for the regulation of food intake
EP1286697A2 (de) *	2000-05-17	2003-03-05	Eli Lilly And Company	Methode zur selektiven hemmung der aktivität von ghrelin
GB0027088D0 (en) *	2000-11-06	2000-12-20	Glaxo Group Ltd	DNA expression vectors
CA2440197A1 (en) *	2001-02-19	2002-08-29	Pharmexa A/S	Synthetic vaccines comprising polyhydroxypolymer carriers
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens

2003
- 2003-09-12 AU AU2003263150A patent/AU2003263150A1/en not_active Abandoned
- 2003-09-12 EP EP03794825A patent/EP1539232A1/de not_active Withdrawn
- 2003-09-12 CA CA002498739A patent/CA2498739A1/en not_active Abandoned
- 2003-09-12 WO PCT/DK2003/000592 patent/WO2004024183A1/en not_active Ceased
- 2003-09-12 JP JP2004535024A patent/JP2006504413A/ja active Pending
- 2003-09-12 MX MXPA05002699A patent/MXPA05002699A/es not_active Application Discontinuation
2005
- 2005-04-11 NO NO20051779A patent/NO20051779L/no unknown

Also Published As

Publication number	Publication date
EP1539232A1 (de)	2005-06-15
AU2003263150A1 (en)	2004-04-30
CA2498739A1 (en)	2004-03-25
NO20051779D0 (no)	2005-04-11
MXPA05002699A (es)	2005-09-20
WO2004024183B1 (en)	2004-05-13
JP2006504413A (ja)	2006-02-09
WO2004024183A1 (en)	2004-03-25

Similar Documents

Publication	Publication Date	Title
NO20023961L (no)	2002-08-20	Ny fremgangsmate for nedregulering av amyloid
MY144532A (en)	2011-09-30	Novel method for down-regulation of amyloid
WO2001005820A3 (en)	2001-07-19	Method for down-regulating gdf-8 activity
MXPA02007796A (es)	2003-12-08	Metodo novedoso para la disminucion de cuerpos amiloides.
US9795666B2 (en)	2017-10-24	High-yield transgenic mammalian expression system for generating virus-like particles
PT1117421E (pt)	2004-11-30	Novos metodos para vacinacao terapeutica
Orellana-Escobedo et al.	2015	An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice
Yang et al.	2009	Novel T-cell epitopes of ovalbumin in BALB/c mouse: potential for peptide-immunotherapy
NO20051779L (no)	2005-04-11	Immunisering mot autologt ghrelin
ES2662022T3 (es)	2018-04-05	Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas
DE69716240D1 (de)	2002-11-14	Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
Fomsgaard et al.	1999	Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NP CTL-epitopes
NO20040431L (no)	2004-04-16	Ny fremgangsmate for nedregulering av amyloid
Karunakaran et al.	2024	Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development
US20190151440A1 (en)	2019-05-23	Mosaic conserved region hiv immunogenic polypeptides
Zeng et al.	2005	Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH
CN119013040A (zh)	2024-11-22	冠状病毒疫苗
US9534020B2 (en)	2017-01-03	Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide
EA200500480A1 (ru)	2005-08-25	Иммунизация против аутологичного грелина
MY135691A (en)	2008-06-30	Method for down-regulation of gdf-8 activity
ECSP003580A (es)	2000-10-24	Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8
Hospers et al.	2009	Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen
Herrera et al.	1999	Effect of different adjuvants and immunomodulators on the humoral immune response of rabbits and mice against HIV-1 derived multi-epitope polypeptides
Grimaldi et al.	2007	Stimulation of pneumovirus-specific CD8+ T-cells using a non-toxic recombinant ricin delivery system
BR102016010178A2 (pt)	2017-11-07	Chemical products with potential use as antigenic diagnostic markers and / or recombinant vaccines against toxoplasmose formed through the junction of bet epitopes of ama-1, gra-7 and sag-1 proteins of toxoplasma gondii